Reprogramming of hematological malignancies
| Project/Area Number |
21790924
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Hematology
|
|---|
| Research Institution | Keio University |
|---|
Principal Investigator |
MATSUKI Eri Keio University, 医学部, 研究員 (80468503)
|
|---|
| Project Period (FY) |
2009 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,290,000 (Direct Cost: ¥3,300,000、Indirect Cost: ¥990,000)
Fiscal Year 2010: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2009: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 造血器腫瘍 / リプログラミング |
|---|
| Research Abstract |
The current research aimed on identifying the mechanism of transformation of low grade hematological malignancies into a highly aggressive tumor, and to develop novel therapeutics for these types of tumors through reprogramming technology. In order to understand the mechanism of transformation in hematological malignancies, we also focused on a rare subtype of lymphoma called plasmablastic lymphoma, and identified that the aberrant expression of Xbp1(s) led to the transformation into plasmablastic appearance, and that inhibition of Xbp1(s) through a proteasome inhibitor bortezomib harbored a potential for treatment for this type of lymphoma.
|
Report
(3 results)
Research Products
(4 results)
